TAF11 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL17749835	1.00	1/20
SCHEMBL29666958	1.00	1/20
SCHEMBL27401699	0.86	1/20
SCHEMBL17749793	0.77	1/20
SCHEMBL17749720	0.76	1/20
SCHEMBL19640307	0.76	1/20
SCHEMBL27401702	0.69	1/20
SCHEMBL24366160	0.67	1/20
SCHEMBL17758434	0.67	1/20
SCHEMBL17758450	0.67	1/20
SCHEMBL17758433	0.66	1/20
SCHEMBL17758602	0.64	1/20
SCHEMBL30073457	0.64	1/20
SCHEMBL17749882	0.62	1/20
SCHEMBL17758439	0.62	1/20
SCHEMBL30073309	0.62	1/20
SCHEMBL20644239	0.61	1/20
SCHEMBL30373817	0.61	1/20
SCHEMBL19640345	0.61	1/20
SCHEMBL30073290	0.60	1/20

Clinical trials — most relevant to TAF11 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
A Study of Bezafibrate in Mitochondrial Myopathy	PHASE2	COMPLETED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma	PHASE1/PHASE2	COMPLETED
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL	PHASE1/PHASE2	RECRUITING
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load	PHASE1	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
Spironolactone and XPB-1 Integrity in the TFIIH Complex	nan	ENROLLING_BY_INVITATION
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics	nan	UNKNOWN
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants.	nan	UNKNOWN
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes	nan	COMPLETED
Immune Interactions in Severe Asthma	nan	COMPLETED
Rare Diseases Clinical Research Network: Neurophysiological Correlates	nan	COMPLETED
Amyotrophic Lateral Sclerosis (ALS) Families Project	nan	RECRUITING
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients	nan	ACTIVE_NOT_RECRUITING
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia	nan	NOT_YET_RECRUITING
Telomere and Telomerase	nan	WITHDRAWN
Familial Investigations of Childhood Cancer Predisposition	nan	RECRUITING
Study for the Multidimensional Analyses of Resistance and Toxicity to Immune- and Targeted-therapies.	nan	UNKNOWN
Novel Biomarkers in the Neoplastic Progression of Barrett's Esophagus	nan	ACTIVE_NOT_RECRUITING
Gene Expression Variation and Implant Wound Healing Among Smokers and Diabetics	nan	COMPLETED
Evaluation of Vasopressin in the Vessels of Ovarian Neoplasms	nan	COMPLETED
Prevalence of a Non-Expressing 11B Mutation in Aka Peoples of the Central African Republic	nan	COMPLETED
Family Resilience Initiative Research Program	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a TAF11 binder may also engage these)

Protein	Name	Similarity
Q5RA91	—	1.000	Q5RA91 →
Q99JX1	—	1.000	Q99JX1 →
A0A1W2PPE2	—	0.999	A0A1W2PPE2 →
P0DW12	—	0.998	P0DW12 →
Q5U1X0	—	0.998	Q5U1X0 →
A0A1W2PPH5	—	0.998	A0A1W2PPH5 →
A0A1W2PRV1	—	0.997	A0A1W2PRV1 →
P49906	—	0.997	P49906 →
A0A1W2PPL8	—	0.997	A0A1W2PPL8 →
B4MVH6	—	0.993	B4MVH6 →
O74857	—	0.992	O74857 →
B2GUV7	—	0.991	B2GUV7 →
Q8BHX3	—	0.991	Q8BHX3 →
P25210	—	0.991	P25210 →
P32832	—	0.991	P32832 →
O60171	—	0.991	O60171 →
EIF5B	Eukaryotic translation initiation factor 5B	0.990	landscape →
O18216	—	0.990	O18216 →
P25208	—	0.990	P25208 →
P11747	—	0.990	P11747 →
A0A1W2PPW3	—	0.990	A0A1W2PPW3 →
Q1MTR4	—	0.989	Q1MTR4 →
Q9US54	—	0.989	Q9US54 →
O23310	—	0.989	O23310 →
O59800	—	0.989	O59800 →
Q9VWD4	—	0.989	Q9VWD4 →
O94667	—	0.989	O94667 →
Q54WG6	—	0.989	Q54WG6 →
Q8K0V4	—	0.989	Q8K0V4 →
P87174	—	0.989	P87174 →